entitled to), €52,016 (approximately C$80,230) settled interest payable, and €25,000 (approximately C$38,560) settled legal fees. A total of 4,700,000 Common Shares of the Company were issued to the vendor with a recorded fair-value as at December 31, 2020 of €22,000,000 (approximately C$34,337,600) (the “Earn-Out Payment”). The Company’s short form prospectus dated November 13, 2020 in respect of the offering of 2,571,500 units disclosed that $16,000,000 of proceeds from that offering were expected to be used for the Earn-Out Cash Payment. The variance of $1,888,730 from that disclosure is due to the additional receivables that were paid (or collected by) K.A.V.O. and interest accrued on the outstanding balance of the Earn-Out Payment.
(6)
On January 21, 2021, the Company announced that it elected to exercise its right under the terms of a warrant indenture dated November 18, 2020 governing certain outstanding warrants of the Company issued on November 18, 2020 to accelerate the expiry date of the warrants. Accordingly, the Company gave notice to all registered warrant holders that the expiry date for the warrants was accelerated to February 22, 2021. During the period from January 1, 2021 to February 22, 2021 a total of 1,554,082 warrants were exercised for cash receipts of C$15,540,822 and a total of 160,547 broker warrants were exercised for cash receipts of C$1,123,742 (together with the Private Placement, exercise of restricted share units and the Earn-Out Payment, the “Capital Transactions”). 4,703 of outstanding warrants expired resulting in a warrants balance of nil after giving effect to the Capital Transactions.
(7)
On January 4, 2021 the Company issued 50,000 Common Shares for the exercise of 50,000 restricted share units with a recorded fair value of C$410,000.
SECONDARY OFFERING BY SELLING SECURITYHOLDERS
Securities may be sold under this Prospectus by way of a secondary offering by or for the account of certain Selling Securityholders. The Prospectus Supplement for or including any offering of Securities by Selling Securityholders will include the following information, to the extent required by applicable securities laws:
•
the name or names of the Selling Securityholders;
•
the number or amount of Securities owned, controlled or directed by each Selling Securityholder;
•
the number or amount of Securities being distributed for the account of each Selling Securityholder;
•
the number or amount of Securities to be owned, controlled or directed by the Selling Securityholders after the distribution and the percentage that number or amount represents of the total number of the Company’s outstanding Securities;
•
whether the Securities are owned by the Selling Securityholders both of record and beneficially, of record only, or beneficially only;
•
if the Selling Securityholder purchased any of the Securities in the 24 months preceding the date of the applicable Prospectus Supplement, the date or dates the Selling Securityholder acquired the Securities;
•
if the Selling Securityholder acquired any of the Securities in the 12 months preceding the date of the applicable Prospectus Supplement, the cost thereof to the Selling Securityholder in aggregate and on an average-cost-per-security basis;
•
if applicable, the disclosure required by item 1.11 of Form 41-101F1, and if applicable, the Selling Securityholders will file a non-issuer’s submission to jurisdiction form with the corresponding Prospectus Supplement; and
•
all other information that is required to be included in the applicable Prospectus Supplement.
DESCRIPTION OF THE SHARE CAPITAL
The authorized capital of the Company consists of an unlimited number of Common Shares. As at May 3, 2021, there were 19,823,814 Common Shares issued and outstanding. As at May 3, 2021, there were also (i) options to acquire 1,225,271 Common Shares, 115,000 restricted share units, 120,000 performance shares units and 253,800 deferred share units granted under the Company’s Omnibus Equity Incentive Plan; and (ii) 16,886 broker warrants issued and outstanding, each broker warrant convertible to one Common Share and one half of one warrant with an exercise price of C$7.00. These figures reflect the 10:1 consolidation described under “Summary Description of the Business — Recent Developments — Share Consolidation”.
USE OF PROCEEDS
Under the Prospectus and applicable Prospectus Supplements, the Company may from time to time offer and issue Securities having an initial offering price of up to $500,000,000 in aggregate (or the equivalent